Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals - - BioPharm International

ADVERTISEMENT

Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals


BioPharm International
Volume 19, Issue 8

13. Velander WH, Johnson JL, Page RL, Russell CG, Subramanian A, Wilkins TD, Gwazdauskas FC, Pittius C, Drohan WN. High level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein. Proc Natl Acad Sci USA 1992; 89:12003-12007.

14. Paleyanda RK, Velander WH, Lee TK, Scandella DH, Gwazdauskas FC, Knight JW, Hoyer LW, Drohan WN, Lubon H. Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol 1997; 15:971-975.

15. Van Cott KE, Butler SP, Russell CG, Subramanian A, Lubon H, Gwazdauskas FC, Knight J, Drohan WN, Velander WH. Transgenic pigs as bio-reactors: a comparison of gamma-carboxylation of glutamic acid in recombinant human protein C and factor IX by the mammary gland. Genet Anal Biomol Eng 1999; 15:155-160.

16. Lubon H and Paleyanda RK. Vitamin K-dependent protein production in transgenic animals. Thromb Haemost 1997; 78:532-536.

17. Clark AJ, Bessos H, Bishop JO, Brown P, Harris S, Lathe R, McClenaghan M, Prowse C, Simons JP, Whitelaw CBA, Wilmut I. Expression of human anti-hemophilic factor IX in the milk of transgenic sheep. Bio/Technology 1989; 7:487-492.

18. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91, 4561-4571.

19. Ziomek C, Kutzko J, Sherman L, Gavin W, Hendry C, Hayes M, Cole ES. Viral and prion safety of recombinant human antithrombin. Ann Hematol 2003; 82(Suppl 1):S95.

20. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio J, Despotis GJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102:276-284.

21. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130:107-113.

22. Tait RC, Morfini M, Walker ID, Makris M, Dolan G, Menon R, Noonan PK, Frieling J, Bonfiglio J. Pharmacokinetics of recombinant human antithrombin in hereditary antithrombin deficient patients. Blood 2002; 100: Abst 3970.

23. Tait RC, Konkle BA, Bauer KA, Bonfiglio J, Dolan G, Frieling J, Greist A, Holmes HE, Makris M, Morfini M, Noonan B, Streisand JB, Weinstein R, Walker ID, Echelard Y. Clinical application of recombinant human antithrombin (AT) in patients with hereditary deficiency. Ann Hematol 2003; 82:S84.

24. Konkle BA, Bauer, KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43:390-394.

25. GTC Biotherapeutics. Press Release. 2006 June 2. Available at http://www.gtc-bio.com/


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here